Evidence map›Paper›PMID 30545715›Full record

ArticleVaccine2019

Strengthening national vaccine decision-making: Assessing the impact of SIVAC Initiative support on national immunisation technical advisory group (NITAG) functionality in 77 low and middle-income countries.

Kevin van Zandvoort, Natasha Howard, Sandra Mounier-Jack, Mark Jit

Abstract read
In one paragraph

Article in Vaccine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kevin van ZandvoortDepartment of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT London, United Kingdom. Electronic address: Kevin.Van-Zandvoort@lshtm.ac.uk.
Natasha HowardDepartment of Global Health and Development, Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, 14-17 Tavistock Place, WC1H 9SH London, United Kingdom. Electronic address: Natasha.Howard@lshtm.ac.uk.
Sandra Mounier-JackDepartment of Global Health and Development, Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, 14-17 Tavistock Place, WC1H 9SH London, United Kingdom. Electronic address: Sandra.Mounier-Jack@lshtm.ac.uk.
Mark JitDepartment of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT London, United Kingdom; Modelling and Economics Unit, Public Health England, 61 Colindale Avenue, NW9 5EQ London, United Kingdom. Electronic address: Mark.Jit@lshtm.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNational Immunisation Technical Advisory Groups (NITAGs) are multi-disciplinary expert groups that provide policy-makers with independent, evidence-based advice on vaccination. Between 2008 and 2017, the SIVAC Initiative supported establishment and strengthening of NITAGs in low and lower-middle income countries though its impact was never assessed quantitatively.

aimTo quantitatively assess whether SIVAC support is associated with a faster rate at which NITAGs became functional based on six performance indicators.

methodsData from the World Health Organization/Unicef Joint Reporting Form (JRF) from 77 low and lower-middle-income countries were used to examine the time delay between the start of SIVAC support and NITAG functionality using a Cox proportional hazards model.

resultsCountries receiving SIVAC support took a mean of 2.00 (95% CI 1.40-2.60) years to reported functionality compared to 2.82 (95% CI 2.05-3.59) years for countries without SIVAC support. We found evidence that SIVAC support is associated with reduced time until NITAG functionality, and this association cannot fully be explained by GDP per capita, percentage of GDP spent on healthcare, or NITAG functionality score at the start of the study period. However, quality of JRF data for the questions used to calculate NITAG functionality were poor, particularly for countries not receiving SIVAC support.

conclusionSIVAC support is likely to have enabled many countries to more rapidly achieve NITAG functionality.

Indexed as

Decision MakingHealth PolicyImmunization ProgramsAdministrative PersonnelAdvisory CommitteesDeveloping CountriesHumansProportional Hazards ModelsUnited NationsVaccinationWorld Health OrganizationLow and middle-income countriesNITAGSIVACVaccinationVaccine policy

Identifiers

PMID30545715
PMCPMC6334253

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.